Keyphrases
Activation Time
8%
Acute Decompensated Heart Failure
23%
Anticholinergic Burden
17%
Anticoagulants
7%
At Discharge
11%
Atrial Fibrillation
8%
Brain-dead Donor
7%
Cardiac Transplantation
11%
Care Program
7%
Clinical Characteristics
11%
Clinical Course
11%
Constipation
12%
COVID-19
11%
Delirium
24%
Direct Oral Anticoagulants
9%
Drug-related Problems
24%
Emergency Department
100%
Emergency Patients
23%
Emergency Room
14%
Emergency Service
10%
Escherichia Coli
9%
Extended Infusion
9%
First Medical Contact
7%
Frail Elderly
13%
Frailty
14%
Hospital Emergency Department
11%
Hospitalized Patients
8%
Ictus
11%
Interdisciplinary Programs
7%
Intestinal Inflammation
11%
Ischemic Stroke
7%
Modified Rankin Scale
7%
Multidrug-resistant Bacteria
8%
Multivariate Analysis
8%
National Institutes of Health Stroke Scale (NIHSS)
9%
Older Adults
7%
Oral Anticoagulants
11%
Pharmacist Care
11%
Pharmacy Medicines
11%
Piperacillin-tazobactam
11%
Primary PCI
11%
Probability of Target Attainment
8%
Retrospective Observational Study
8%
Risk Factors
11%
Septic Patients
11%
ST-elevation Myocardial Infarction (STEMI)
15%
Therapeutic Management
7%
Transplantation
7%
Urinary Tract Infection
11%
Vitamin K Antagonists
7%
Medicine and Dentistry
Action Potential
7%
Acute Pancreatitis
5%
Alteplase
5%
Antithrombotic
11%
Apoplexy
18%
Atrial Fibrillation
6%
Backache
5%
Brain Ischemia
7%
Cardiovascular Risk
5%
Cerebral Hemorrhage
7%
Cerebrovascular Disease
11%
Clinical Trial
6%
Comorbidity
13%
Consultation
13%
COVID-19
11%
D-Dimer
7%
Decompensated Heart Failure
11%
Delirium
12%
Digestive System Hemorrhage
6%
Direct Oral Anticoagulant
7%
Diseases
7%
Door-to-Balloon
5%
Drug Therapy
16%
Electrocardiogram
9%
Emergency Care
6%
Emergency Department
79%
Emergency Medicine
12%
Escherichia coli
5%
Frailty
5%
Health System
6%
Heart Muscle Injury
5%
Heart Transplantation
13%
Hospital Mortality
5%
Hospital Pharmacy
11%
Infection
8%
Kidney Transplantation
5%
Mortality Rate
10%
Muscle Cell
5%
National Institutes of Health Stroke Scale
7%
Nurse
10%
Observational Study
9%
Ornithine Transcarbamylase Deficiency
5%
Percutaneous Coronary Intervention
12%
Pharmaceutical Care
6%
Programmed Cell Death
5%
Pulmonary Embolism
5%
Retrospective Study
7%
Risk Stratification
6%
Tocilizumab
7%
Triage
14%
Pharmacology, Toxicology and Pharmaceutical Science
Abdominal Pain
5%
Acute Heart Infarction
5%
Alpha Adrenergic Receptor Stimulating Agent
5%
Anticoagulant Agent
11%
Antiinfective Agent
5%
Backache
5%
Base
5%
Cardiovascular Risk
5%
Cefepime
5%
Cerebrovascular Accident
17%
Cerebrovascular Disease
11%
Cholinergic Receptor Blocking Agent
17%
Comorbidity
18%
Congestive Heart Failure
5%
Constipation
11%
Coronavirinae
5%
Croton Oil
6%
D Dimer
7%
Delirium
5%
Disease
9%
Enteritis
11%
Escherichia coli
10%
Frailty
5%
Functional Status
5%
Gangrene
5%
Heart Infarction
5%
Hospital Mortality
5%
Hospital Pharmacy
11%
Infection
8%
Inflammation
9%
Lactic Acidosis
5%
Lung Embolism
5%
Meningitis
5%
Metformin
5%
Minimum Inhibitory Concentration
5%
Morphine
5%
Mortality Rate
9%
Observational Study
11%
Ornithine Transcarbamylase Deficiency
5%
Pharmacodynamics
6%
Pharmacokinetics
6%
Pharmacotherapy
9%
Piperacillin Plus Tazobactam
11%
Rendu Osler Weber Disease
5%
Retrospective Study
17%
Somnolence
5%
Survival Rate
6%
Syndrome
5%
Tocilizumab
7%
Urinary Tract Infection
11%
